With Approval Pending, Pegcetacoplan Phase 3 Results Mixed

With an FDA action date set, investigative complement inhibitor pegcetacoplan showed a signal for improving visual function in geographic atrophy but also a risk for conversion to wet AMD.
Medscape Medical News